{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:37:15Z","timestamp":1794487035619,"version":"4.9.1"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"DOI":"10.1038\/s41575-026-01240-6","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:23:31Z","timestamp":1787052211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Global epidemiology of metabolic and alcohol-associated liver disease: risk factors, natural history and clinical implications"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8540-4930","authenticated-orcid":false,"given":"Luis Antonio","family":"D\u00edaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Pose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9443-5846","authenticated-orcid":false,"given":"Mads","family":"Israelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-9991","authenticated-orcid":false,"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"1240_CR1","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","volume":"404","author":"M Israelsen","year":"2024","unstructured":"Israelsen, M., Francque, S., Tsochatzis, E. A. & Krag, A. Steatotic liver disease. Lancet 404, 1761\u20131778 (2024).","journal-title":"Lancet"},{"key":"1240_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","volume":"11","author":"DQ Huang","year":"2025","unstructured":"Huang, D. Q. et al. Metabolic dysfunction-associated steatotic liver disease in adults. Nat. Rev. Dis. Primers 11, 14 (2025).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1240_CR3","unstructured":"World Health Organization. Global Status Report on Alcohol and Health and Treatment of Substance Use Disorders https:\/\/www.who.int\/publications\/i\/item\/9789240096745 (WHO, 2024)."},{"key":"1240_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s43856-024-00649-x","volume":"4","author":"LA D\u00edaz","year":"2024","unstructured":"D\u00edaz, L. A. et al. Disparities in steatosis prevalence in the United States by race or ethnicity according to the 2023 criteria. Commun. Med. 4, 219 (2024).","journal-title":"Commun. Med."},{"key":"1240_CR5","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78, 1966\u20131986 (2023). This is the 2023 consensus that framed the MetALD definition.","journal-title":"Hepatology"},{"key":"1240_CR6","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S2468-1253(23)00206-6","volume":"8","author":"M Israelsen","year":"2023","unstructured":"Israelsen, M., Torp, N., Johansen, S., Thiele, M. & Krag, A. MetALD: new opportunities to understand the role of alcohol in steatotic liver disease. Lancet Gastroenterol. Hepatol. 8, 866\u2013868 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1240_CR7","doi-asserted-by":"publisher","first-page":"101250","DOI":"10.1016\/j.jhepr.2024.101250","volume":"7","author":"J Gratac\u00f3s-Gin\u00e8s","year":"2025","unstructured":"Gratac\u00f3s-Gin\u00e8s, J., Ari\u00f1o, S., Sancho-Bru, P., Bataller, R. & Pose, E. MetALD: clinical aspects, pathophysiology and treatment. JHEP Rep. 7, 101250 (2025).","journal-title":"JHEP Rep."},{"key":"1240_CR8","doi-asserted-by":"publisher","unstructured":"D\u00edaz, L. A., Arab, J. P., Louvet, A., Bataller, R. & Arrese, M. The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1038\/s41575-023-00822-y (2023).","DOI":"10.1038\/s41575-023-00822-y"},{"key":"1240_CR9","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","volume":"405","author":"GBD 2021 Adult BMI Collaborators","year":"2025","unstructured":"GBD 2021 Adult BMI Collaborators Global, regional, and national prevalence of adult overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet 405, 813\u2013838 (2025).","journal-title":"Lancet"},{"key":"1240_CR10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"GBD 2021 Diabetes Collaborators","year":"2023","unstructured":"GBD 2021 Diabetes Collaborators Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203\u2013234 (2023).","journal-title":"Lancet"},{"key":"1240_CR11","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1016\/j.cgh.2025.02.006","volume":"23","author":"GJK Ho","year":"2025","unstructured":"Ho, G. J. K. et al. High global prevalence of steatotic liver disease and associated subtypes: a meta-analysis. Clin. Gastroenterol. Hepatol. 23, 2423\u20132432 (2025).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1240_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000947","volume":"10","author":"P Danpanichkul","year":"2026","unstructured":"Danpanichkul, P., Idalsoaga, F., Murray, F., Arab, J. P. & D\u00edaz, L. A. The global epidemiology of alcohol-associated liver disease. Hepatol. Commun. 10, e0947 (2026).","journal-title":"Hepatol. Commun."},{"key":"1240_CR13","doi-asserted-by":"publisher","first-page":"879","DOI":"10.7326\/M23-0518","volume":"176","author":"BP Lee","year":"2023","unstructured":"Lee, B. P., Dodge, J. L., Mack, W. J., Leventhal, A. M. & Terrault, N. A. National trends in alcohol use, metabolic syndrome, and liver disease from 1999 to 2018. Ann. Intern. Med. 176, 879\u2013882 (2023).","journal-title":"Ann. Intern. Med."},{"key":"1240_CR14","doi-asserted-by":"publisher","unstructured":"Arab, J. P. et al. Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease. J. Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2024.11.028 (2024).","DOI":"10.1016\/j.jhep.2024.11.028"},{"key":"1240_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70017","volume":"45","author":"G Ayares","year":"2025","unstructured":"Ayares, G. et al. MetALD: New perspectives on an old overlooked disease. Liver Int. 45, e70017 (2025).","journal-title":"Liver Int."},{"key":"1240_CR16","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1002\/hep.32743","volume":"77","author":"A Kardashian","year":"2023","unstructured":"Kardashian, A., Serper, M., Terrault, N. & Nephew, L. D. Health disparities in chronic liver disease. Hepatology 77, 1382\u20131403 (2023).","journal-title":"Hepatology"},{"key":"1240_CR17","doi-asserted-by":"publisher","unstructured":"D\u00edaz, L. A. et al. Management of alcohol use disorder: a gastroenterology and hepatology-focused perspective. Lancet Gastroenterol. Hepatol. https:\/\/doi.org\/10.1016\/S2468-1253(24)00380-7 (2025).","DOI":"10.1016\/S2468-1253(24)00380-7"},{"key":"1240_CR18","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","volume":"81","author":"D Marti-Aguado","year":"2024","unstructured":"Marti-Aguado, D. et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease. J. Hepatol. 81, 930\u2013940 (2024). This article elucidated the role of alcohol use in the development of significant fibrosis within the MASLD and MetALD spectrum.","journal-title":"J. Hepatol."},{"key":"1240_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-7987-3","volume":"19","author":"C Gilligan","year":"2019","unstructured":"Gilligan, C., Anderson, K. G., Ladd, B. O., Yong, Y. M. & David, M. Inaccuracies in survey reporting of alcohol consumption. BMC Public Health 19, 1639 (2019).","journal-title":"BMC Public Health"},{"key":"1240_CR20","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S2468-1253(24)00427-8","volume":"10","author":"A Krag","year":"2025","unstructured":"Krag, A., Torp, N., Younossi, Z. M. & Israelsen, M. Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD. Lancet Gastroenterol. Hepatol. 10, 282\u2013284 (2025).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1240_CR21","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2022.04.026","volume":"77","author":"G Schomerus","year":"2022","unstructured":"Schomerus, G. et al. The stigma of alcohol-related liver disease and its impact on healthcare. J. Hepatol. 77, 516\u2013524 (2022).","journal-title":"J. Hepatol."},{"key":"1240_CR22","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S2468-1253(23)00443-0","volume":"9","author":"M Israelsen","year":"2024","unstructured":"Israelsen, M. et al. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol. Hepatol. 9, 218\u2013228 (2024).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1240_CR23","doi-asserted-by":"publisher","first-page":"101172","DOI":"10.1016\/j.jhepr.2024.101172","volume":"6","author":"V M\u00e4nnist\u00f6","year":"2024","unstructured":"M\u00e4nnist\u00f6, V. et al. ALT levels, alcohol use, and metabolic risk factors have prognostic relevance for liver-related outcomes in the general population. JHEP Rep. 6, 101172 (2024).","journal-title":"JHEP Rep."},{"key":"1240_CR24","doi-asserted-by":"publisher","unstructured":"Israelsen, M., Tr\u00e9po, E., Krag, A. & Stender, S. MetALD: genetic factors and clinical outcomes. Semin. Liver Dis. https:\/\/doi.org\/10.1055\/a-2630-0952 (2025).","DOI":"10.1055\/a-2630-0952"},{"key":"1240_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000145","volume":"7","author":"JL Mellinger","year":"2023","unstructured":"Mellinger, J. L., Fernandez, A. C. & Winder, G. S. Management of alcohol use disorder in patients with chronic liver disease. Hepatol. Commun. 7, e00145 (2023).","journal-title":"Hepatol. Commun."},{"key":"1240_CR26","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41575-024-01022-y","volume":"22","author":"N Torp","year":"2025","unstructured":"Torp, N., Israelsen, M. & Krag, A. The steatotic liver disease burden paradox: unravelling the key role of alcohol. Nat. Rev. Gastroenterol. Hepatol. 22, 281\u2013292 (2025).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1240_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/acer.14512","volume":"45","author":"J Arnts","year":"2021","unstructured":"Arnts, J. et al. Diagnostic accuracy of biomarkers of alcohol use in patients with liver disease: a systematic review. Alcohol Clin. Exp. Res. 45, 25\u201337 (2021).","journal-title":"Alcohol Clin. Exp. Res."},{"key":"1240_CR28","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1097\/HEP.0000000000000885","volume":"80","author":"M Israelsen","year":"2024","unstructured":"Israelsen, M., Rungratanawanich, W., Thiele, M. & Liangpunsakul, S. Non-invasive tests for alcohol-associated liver disease. Hepatology 80, 1390\u20131407 (2024).","journal-title":"Hepatology"},{"key":"1240_CR29","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.dld.2024.01.195","volume":"56","author":"K Scholten","year":"2024","unstructured":"Scholten, K. et al. You can\u2019t handle the truth! Comparing serum phosphatidylethanol to self-reported alcohol intake in chronic liver disease patients. Dig. Liver Dis. 56, 1215\u20131219 (2024).","journal-title":"Dig. Liver Dis."},{"key":"1240_CR30","doi-asserted-by":"publisher","first-page":"101200","DOI":"10.1016\/j.jhepr.2024.101200","volume":"7","author":"ED Hansen","year":"2025","unstructured":"Hansen, E. D. et al. Quantification of alcohol intake in patients with steatotic liver disease and excessive alcohol intake. JHEP Rep. 7, 101200 (2025).","journal-title":"JHEP Rep."},{"key":"1240_CR31","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jhep.2022.04.040","volume":"77","author":"K Staufer","year":"2022","unstructured":"Staufer, K. et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. J. Hepatol. 77, 918\u2013930 (2022). Landmark study evidencing the under-reporting of alcohol use in presumed MASLD.","journal-title":"J. Hepatol."},{"key":"1240_CR32","doi-asserted-by":"publisher","unstructured":"Vaz, J. et al. Phosphatidylethanol levels distinguish steatotic liver disease subgroups and are associated with risk of major liver outcomes. J. Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2025.04.019 (2025). A relevant study evidencing that PEth can be a better prognostic marker than self-reported alcohol use in SLD.","DOI":"10.1016\/j.jhep.2025.04.019"},{"key":"1240_CR33","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1080\/00365521.2016.1239759","volume":"52","author":"H Hagstr\u00f6m","year":"2017","unstructured":"Hagstr\u00f6m, H. et al. Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. Scand. J. Gastroenterol. 52, 159\u2013165 (2017).","journal-title":"Scand. J. Gastroenterol."},{"key":"1240_CR34","doi-asserted-by":"publisher","unstructured":"Tavaglione, F. et al. Head-to-head comparison between phosphatidylethanol versus indirect alcohol biomarkers for diagnosis of MetALD versus MASLD: a prospective study. Aliment. Pharmacol. Ther. https:\/\/doi.org\/10.1111\/apt.18506 (2025).","DOI":"10.1111\/apt.18506"},{"key":"1240_CR35","doi-asserted-by":"publisher","unstructured":"Tavaglione, F. et al. Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification. J. Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2025.05.030 (2025). A landmark study validating the cut points of PEth to identify MetALD and ALD in SLD.","DOI":"10.1016\/j.jhep.2025.05.030"},{"key":"1240_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41575-022-00688-6","volume":"20","author":"DQ Huang","year":"2023","unstructured":"Huang, D. Q., Mathurin, P., Cortez-Pinto, H. & Loomba, R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat. Rev. Gastroenterol. Hepatol. 20, 37\u201349 (2023).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1240_CR37","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/dar.13286","volume":"40","author":"J Rehm","year":"2021","unstructured":"Rehm, J. et al. The role of alcohol use in the aetiology and progression of liver disease: a narrative review and a quantification. Drug Alcohol Rev. 40, 1377\u20131386 (2021).","journal-title":"Drug Alcohol Rev."},{"key":"1240_CR38","doi-asserted-by":"publisher","DOI":"10.1097\/CLD.0000000000000192","volume":"23","author":"H Desalegn","year":"2024","unstructured":"Desalegn, H., Diaz, L. A., Rehm, J. & Arab, J. P. Impact of alcohol use on liver disease outcomes. Clin. Liver Dis. 23, e0192 (2024).","journal-title":"Clin. Liver Dis."},{"key":"1240_CR39","doi-asserted-by":"publisher","unstructured":"Danpanichkul, P. et al. Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000\u20132021. Clin. Mol. Hepatol. https:\/\/doi.org\/10.3350\/cmh.2024.0835 (2025).","DOI":"10.3350\/cmh.2024.0835"},{"key":"1240_CR40","doi-asserted-by":"publisher","unstructured":"Yang, A. H. et al. Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA. Gut https:\/\/doi.org\/10.1136\/gutjnl-2024-332917 (2024).","DOI":"10.1136\/gutjnl-2024-332917"},{"key":"1240_CR41","unstructured":"World Health Organization. Obesity and Overweight (WHO, 2025) https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight (WHO, 2025)."},{"key":"1240_CR42","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(24)02317-1","volume":"404","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2024","unstructured":"NCD Risk Factor Collaboration (NCD-RisC) Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet 404, 2077\u20132093 (2024).","journal-title":"Lancet"},{"key":"1240_CR43","doi-asserted-by":"publisher","unstructured":"Kalligeros, M. et al. Prevalence of steatotic liver disease (MASLD, MetALD and ALD) in the United States: NHANES 2017\u20132020. Clin. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2023.11.003 (2023).","DOI":"10.1016\/j.cgh.2023.11.003"},{"key":"1240_CR44","doi-asserted-by":"publisher","unstructured":"Lee, B. P., Dodge, J. L. & Terrault, N. A. National prevalence estimates for steatotic liver disease and sub-classifications using consensus nomenclature. Hepatology https:\/\/doi.org\/10.1097\/HEP.0000000000000604 (2023).","DOI":"10.1097\/HEP.0000000000000604"},{"key":"1240_CR45","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4067\/s0034-98872024000200187","volume":"152","author":"J P\u00e9rez-Valenzuela","year":"2024","unstructured":"P\u00e9rez-Valenzuela, J., Aguirre, H., Mart\u00ednez, L., Castro, L. & Mezzano, G. Prevalence and clinical associations of steatotic liver disease in a preventive medicine unit: a cross-sectional study. Rev. Med. Chil. 152, 187\u2013196 (2024).","journal-title":"Rev. Med. Chil."},{"key":"1240_CR46","doi-asserted-by":"publisher","first-page":"101919","DOI":"10.1016\/j.aohep.2025.101919","volume":"30","author":"M Spencer-Sandino","year":"2025","unstructured":"Spencer-Sandino, M. et al. New steatotic liver disease criteria diagnostic performance in an agricultural population in Chile. Ann. Hepatol. 30, 101919 (2025).","journal-title":"Ann. Hepatol."},{"key":"1240_CR47","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1016\/j.jhep.2023.08.025","volume":"80","author":"H Perazzo","year":"2024","unstructured":"Perazzo, H., Pacheco, A. G., Griep, R. H. & Collaborators Changing from NAFLD through MAFLD to MASLD: similar prevalence and risk factors in a large Brazilian cohort. J. Hepatol. 80, e72\u2013e74 (2024).","journal-title":"J. Hepatol."},{"key":"1240_CR48","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/hepr.14133","volume":"55","author":"EL Yoon","year":"2025","unstructured":"Yoon, E. L. et al. Distinct characteristics of MetALD (metabolic dysfunction-associated steatotic liver disease with greater alcohol consumption) in the general population. Hepatol. Res. 55, 410\u2013421 (2025).","journal-title":"Hepatol. Res."},{"key":"1240_CR49","doi-asserted-by":"publisher","unstructured":"Lee, C.-M. et al. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings. Hepatology https:\/\/doi.org\/10.1097\/HEP.0000000000000664 (2023).","DOI":"10.1097\/HEP.0000000000000664"},{"key":"1240_CR50","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.3390\/jcm13041158","volume":"13","author":"T Miwa","year":"2024","unstructured":"Miwa, T. et al. Prevalence of steatotic liver disease based on a new nomenclature in the Japanese population: A health checkup-based cross-sectional study. J. Clin. Med. 13, 1158 (2024).","journal-title":"J. Clin. Med."},{"key":"1240_CR51","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/apt.17958","volume":"59","author":"CV Schneider","year":"2024","unstructured":"Schneider, C. V. et al. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population. Aliment. Pharmacol. Ther. 59, 1271\u20131281 (2024).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1240_CR52","doi-asserted-by":"publisher","unstructured":"Hansen, C. D. et al. Prevalence, severity and determinants of steatotic liver disease among individuals with metabolic and alcohol risk from the community. J. Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2025.06.020 (2025).","DOI":"10.1016\/j.jhep.2025.06.020"},{"key":"1240_CR53","doi-asserted-by":"publisher","first-page":"156101","DOI":"10.1016\/j.metabol.2024.156101","volume":"163","author":"M Tampaki","year":"2025","unstructured":"Tampaki, M., Tsochatzis, E., Lekakis, V. & Cholongitas, E. Prevalence, characteristics and outcomes of patients with metabolic and alcohol related\/associated liver disease (MetALD): a systematic review and meta-analysis. Metabolism 163, 156101 (2025).","journal-title":"Metabolism"},{"key":"1240_CR54","doi-asserted-by":"publisher","unstructured":"Paik, J. M. et al. Prevalence of MASLD, met-ALD, and ALD and associated fibrosis among US adults: Insights from NHANES 2017 to 2023. J. Clin. Gastroenterol. https:\/\/doi.org\/10.1097\/MCG.0000000000002202 (2025).","DOI":"10.1097\/MCG.0000000000002202"},{"key":"1240_CR55","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3350\/cmh.2024.0987","volume":"31","author":"D Kim","year":"2025","unstructured":"Kim, D. et al. Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023. Clin. Mol. Hepatol. 31, 382\u2013393 (2025).","journal-title":"Clin. Mol. Hepatol."},{"key":"1240_CR56","doi-asserted-by":"publisher","unstructured":"Lee, D. Y. et al. Characteristics of metabolic dysfunction-associated steatotic liver disease and its risk for hepatic fibrosis in 476,124 Korean adults: a cross-sectional study. Endocrinol. Metab. https:\/\/doi.org\/10.3803\/EnM.2024.2281 (2025).","DOI":"10.3803\/EnM.2024.2281"},{"key":"1240_CR57","doi-asserted-by":"publisher","unstructured":"Liu, J. et al. Dissecting metabolic dysfunction- and alcohol-associated liver disease (MetALD) using proteomic and metabolomic profiles. J. Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2025.05.026 (2025).","DOI":"10.1016\/j.jhep.2025.05.026"},{"key":"1240_CR58","doi-asserted-by":"publisher","first-page":"101907","DOI":"10.1016\/j.aohep.2025.101907","volume":"30","author":"E Kaya","year":"2025","unstructured":"Kaya, E., Vilar-Gomez, E., Vuppalanchi, R. & Yilmaz, Y. Body mass index and diabetes predict severity of liver fibrosis across the spectrum of steatotic liver disease. Ann. Hepatol. 30, 101907 (2025).","journal-title":"Ann. Hepatol."},{"key":"1240_CR59","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000324","volume":"7","author":"P Ochoa-Allemant","year":"2023","unstructured":"Ochoa-Allemant, P., Marrero, J. A. & Serper, M. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States. Hepatol. Commun. 7, e0324 (2023).","journal-title":"Hepatol. Commun."},{"key":"1240_CR60","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1056\/NEJMra2406458","volume":"392","author":"D Gallegos","year":"2025","unstructured":"Gallegos, D. Effects of food and nutrition insecurity on global health. N. Engl. J. Med. 392, 686\u2013697 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1240_CR61","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1177\/19485506211030102","volume":"13","author":"YU Girme","year":"2022","unstructured":"Girme, Y. U., Sibley, C. G., Hadden, B. W., Schmitt, M. T. & Hunger, J. M. Unsupported and stigmatized? The association between relationship status and well-being is mediated by social support and social discrimination. Soc. Psychol. Personal. Sci. 13, 425\u2013435 (2022).","journal-title":"Soc. Psychol. Personal. Sci."},{"key":"1240_CR62","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2018.10.037","volume":"70","author":"M You","year":"2019","unstructured":"You, M. & Arteel, G. E. Effect of ethanol on lipid metabolism. J. Hepatol. 70, 237\u2013248 (2019).","journal-title":"J. Hepatol."},{"key":"1240_CR63","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-020-0128-8","volume":"5","author":"MA Abdallah","year":"2020","unstructured":"Abdallah, M. A. & Singal, A. K. Mitochondrial dysfunction and alcohol-associated liver disease: a novel pathway and therapeutic target. Signal. Transduct. Target. Ther. 5, 26 (2020).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1240_CR64","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41575-018-0099-1","volume":"16","author":"JS Bajaj","year":"2019","unstructured":"Bajaj, J. S. Alcohol, liver disease and the gut microbiota. Nat. Rev. Gastroenterol. Hepatol. 16, 235\u2013246 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1240_CR65","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176345","volume":"134","author":"B Mackowiak","year":"2024","unstructured":"Mackowiak, B., Fu, Y., Maccioni, L. & Gao, B. Alcohol-associated liver disease. J. Clin. Invest. 134, e176345 (2024).","journal-title":"J. Clin. Invest."},{"key":"1240_CR66","doi-asserted-by":"publisher","first-page":"C1637","DOI":"10.1152\/ajpcell.00951.2024","volume":"328","author":"MS Kuchay","year":"2025","unstructured":"Kuchay, M. S., Choudhary, N. S. & Ramos-Molina, B. Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease. Am. J. Physiol. Cell Physiol. 328, C1637\u2013C1666 (2025).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"1240_CR67","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.livres.2018.02.002","volume":"2","author":"R Parker","year":"2018","unstructured":"Parker, R. The role of adipose tissue in fatty liver diseases. Liver Res. 2, 35\u201342 (2018).","journal-title":"Liver Res."},{"key":"1240_CR68","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1172\/JCI134165","volume":"130","author":"GI Smith","year":"2020","unstructured":"Smith, G. I. et al. Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease. J. Clin. Invest. 130, 1453\u20131460 (2020).","journal-title":"J. Clin. Invest."},{"key":"1240_CR69","doi-asserted-by":"publisher","first-page":"8731","DOI":"10.3390\/ijms25168731","volume":"25","author":"S-E Ferdous","year":"2024","unstructured":"Ferdous, S.-E. & Ferrell, J. M. Pathophysiological relationship between type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: novel therapeutic approaches. Int. J. Mol. Sci. 25, 8731 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1240_CR70","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41366-023-01443-w","volume":"48","author":"A Van Eyck","year":"2024","unstructured":"Van Eyck, A. et al. The role of adipose tissue and subsequent liver tissue hypoxia in obesity and early stage metabolic dysfunction associated steatotic liver disease. Int. J. Obes. 48, 512\u2013522 (2024).","journal-title":"Int. J. Obes."},{"key":"1240_CR71","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","volume":"79","author":"AL Hutchison","year":"2023","unstructured":"Hutchison, A. L., Tavaglione, F., Romeo, S. & Charlton, M. Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance. J. Hepatol. 79, 1524\u20131541 (2023).","journal-title":"J. Hepatol."},{"key":"1240_CR72","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-pathol-020117-043617","volume":"13","author":"JP Arab","year":"2018","unstructured":"Arab, J. P., Arrese, M. & Trauner, M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu. Rev. Pathol. 13, 321\u2013350 (2018).","journal-title":"Annu. Rev. Pathol."},{"key":"1240_CR73","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.34221","volume":"5","author":"H-S Kim","year":"2022","unstructured":"Kim, H.-S. et al. Synergistic associations of PNPLA3 I148M variant, alcohol intake, and obesity with risk of cirrhosis, hepatocellular carcinoma, and mortality. JAMA Netw. Open 5, e2234221 (2022).","journal-title":"JAMA Netw. Open"},{"key":"1240_CR74","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16123","volume":"45","author":"J Kozlitina","year":"2025","unstructured":"Kozlitina, J. & Sookoian, S. Global epidemiological impact of PNPLA3 I148M on liver disease. Liver Int. 45, e16123 (2025).","journal-title":"Liver Int."},{"key":"1240_CR75","doi-asserted-by":"publisher","first-page":"5613","DOI":"10.3390\/ijms20225613","volume":"20","author":"G Pennisi","year":"2019","unstructured":"Pennisi, G., Celsa, C., Giammanco, A., Spatola, F. & Petta, S. The burden of hepatocellular carcinoma in non-alcoholic fatty liver disease: screening issue and future perspectives. Int. J. Mol. Sci. 20, 5613 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"1240_CR76","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","volume":"72","author":"E Tr\u00e9po","year":"2020","unstructured":"Tr\u00e9po, E. & Valenti, L. Update on NAFLD genetics: from new variants to the clinic. J. Hepatol. 72, 1196\u20131209 (2020).","journal-title":"J. Hepatol."},{"key":"1240_CR77","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/hep.31238","volume":"72","author":"H Gellert-Kristensen","year":"2020","unstructured":"Gellert-Kristensen, H. et al. Combined effect of PNPLA3, TM6SF2, and HSD17B13 variants on risk of cirrhosis and hepatocellular carcinoma in the general population. Hepatology 72, 845\u2013856 (2020).","journal-title":"Hepatology"},{"key":"1240_CR78","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","volume":"8","author":"J Quek","year":"2023","unstructured":"Quek, J. et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 8, 20\u201330 (2023).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1240_CR79","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","volume":"72","author":"E En Li Cho","year":"2023","unstructured":"En Li Cho, E. et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut 72, 2138\u20132148 (2023).","journal-title":"Gut"},{"key":"1240_CR80","doi-asserted-by":"publisher","first-page":"112","DOI":"10.7326\/0003-4819-132-2-200001180-00004","volume":"132","author":"S Bellentani","year":"2000","unstructured":"Bellentani, S. et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 132, 112\u2013117 (2000).","journal-title":"Ann. Intern. Med."},{"key":"1240_CR81","doi-asserted-by":"publisher","unstructured":"Ochoa-Allemant, P., Hubbard, R. A., Kaplan, D. E. & Serper, M. Adverse liver outcomes, cardiovascular events, and mortality in steatotic liver disease. JAMA Intern. Med. https:\/\/doi.org\/10.1001\/jamainternmed.2025.1809 (2025).","DOI":"10.1001\/jamainternmed.2025.1809"},{"key":"1240_CR82","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S2468-1253(25)00188-8","volume":"10","author":"C Celsa","year":"2025","unstructured":"Celsa, C. et al. Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 10, 998\u20131012 (2025). A recent systematic review evidencing the poorest prognosis of MetALD in comparison with MASLD.","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1240_CR83","doi-asserted-by":"publisher","unstructured":"Yun, B. et al. Liver cancer risk across metabolic dysfunction-associated steatotic liver disease and\/or alcohol: a nationwide study. Am. J. Gastroenterol. https:\/\/doi.org\/10.14309\/ajg.0000000000002920 (2024).","DOI":"10.14309\/ajg.0000000000002920"},{"key":"1240_CR84","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jhep.2018.07.022","volume":"69","author":"N Ganne-Carri\u00e9","year":"2018","unstructured":"Ganne-Carri\u00e9, N. et al. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. J. Hepatol. 69, 1274\u20131283 (2018).","journal-title":"J. Hepatol."},{"key":"1240_CR85","doi-asserted-by":"publisher","first-page":"155800","DOI":"10.1016\/j.metabol.2024.155800","volume":"153","author":"HJ Choe","year":"2024","unstructured":"Choe, H. J., Moon, J. H., Kim, W., Koo, B. K. & Cho, N. H. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a community-dwelling cohort study with 20-year follow-up. Metabolism 153, 155800 (2024).","journal-title":"Metabolism"},{"key":"1240_CR86","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1111\/jgh.16726","volume":"39","author":"MB Aboona","year":"2024","unstructured":"Aboona, M. B. et al. Mortality outcomes in individuals with MASLD versus MASLD and increased alcohol intake. J. Gastroenterol. Hepatol. 39, 2456\u20132463 (2024).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1240_CR87","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi, H. et al. Global burden of liver disease: 2023 update. J. Hepatol. 79, 516\u2013537 (2023).","journal-title":"J. Hepatol."},{"key":"1240_CR88","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.14309\/ajg.0000000000001292","volume":"116","author":"C Ma","year":"2021","unstructured":"Ma, C. et al. Trends in the economic burden of chronic liver diseases and cirrhosis in the United States: 1996\u20132016. Am. J. Gastroenterol. 116, 2060\u20132067 (2021).","journal-title":"Am. J. Gastroenterol."},{"key":"1240_CR89","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.cgh.2016.07.020","volume":"15","author":"M Stepanova","year":"2017","unstructured":"Stepanova, M. et al. Direct and indirect economic burden of chronic liver disease in the United States. Clin. Gastroenterol. Hepatol. 15, 759\u2013766.e5 (2017).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1240_CR90","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.1997","volume":"3","author":"G Hirode","year":"2020","unstructured":"Hirode, G., Saab, S. & Wong, R. J. Trends in the burden of chronic liver disease among hospitalized US adults. JAMA Netw. Open\u00a03, e201997 (2020).","journal-title":"JAMA Netw. Open"},{"key":"1240_CR91","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1097\/HEP.0000000000000914","volume":"81","author":"P Ochoa-Allemant","year":"2025","unstructured":"Ochoa-Allemant, P. et al. Waitlisting and liver transplantation for MetALD in the United States: an analysis of the UNOS national registry. Hepatology 81, 532\u2013545 (2025).","journal-title":"Hepatology"},{"key":"1240_CR92","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/apt.18165","volume":"60","author":"P Sultanik","year":"2024","unstructured":"Sultanik, P. et al. Prevalence and prognosis of patients with MASLD-related cirrhosis after an ICU hospitalization in France: a single-centre prospective study. Aliment. Pharmacol. Ther. 60, 796\u2013810 (2024).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1240_CR93","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1111\/liv.15939","volume":"44","author":"S Ciardullo","year":"2024","unstructured":"Ciardullo, S. et al. Impact of MASLD and MetALD on clinical outcomes: a meta-analysis of preliminary evidence. Liver Int. 44, 1762\u20131767 (2024).","journal-title":"Liver Int."},{"key":"1240_CR94","doi-asserted-by":"publisher","first-page":"101127","DOI":"10.1016\/j.jhepr.2024.101127","volume":"6","author":"P Sripongpun","year":"2024","unstructured":"Sripongpun, P., Kaewdech, A., Udompap, P. & Kim, W. R. Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score. JHEP Rep. 6, 101127 (2024).","journal-title":"JHEP Rep."},{"key":"1240_CR95","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389\u201397.e10 (2015).","journal-title":"Gastroenterology"},{"key":"1240_CR96","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/hep.32163","volume":"75","author":"P Gin\u00e8s","year":"2022","unstructured":"Gin\u00e8s, P. et al. Population screening for liver fibrosis: toward early diagnosis and intervention for chronic liver diseases. Hepatology 75, 219\u2013228 (2022).","journal-title":"Hepatology"},{"key":"1240_CR97","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"European Association for the Study of the Liver","year":"2021","unstructured":"European Association for the Study of the Liver EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis \u2014 2021 update. J. Hepatol. 75, 659\u2013689 (2021).","journal-title":"J. Hepatol."},{"key":"1240_CR98","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.cgh.2023.12.018","volume":"22","author":"M Kjaergaard","year":"2024","unstructured":"Kjaergaard, M. et al. Screening for fibrosis promotes lifestyle changes: a prospective cohort study in 4796 individuals. Clin. Gastroenterol. Hepatol. 22, 1037\u20131047.e9 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1240_CR99","doi-asserted-by":"publisher","first-page":"101165","DOI":"10.1016\/j.jhepr.2024.101165","volume":"6","author":"E Avitabile","year":"2024","unstructured":"Avitabile, E. et al. Liver fibrosis screening increases alcohol abstinence. JHEP Rep. 6, 101165 (2024).","journal-title":"JHEP Rep."},{"key":"1240_CR100","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1053\/j.gastro.2025.07.007","volume":"169","author":"R Loomba","year":"2025","unstructured":"Loomba, R., Hagstr\u00f6m, H. & D\u00edaz, L. A. Emerging role of phosphatidylethanol testing in clinical practice for the identification of steatotic liver disease subtypes: is this the new standard? Gastroenterology 169, 1103\u20131107 (2025).","journal-title":"Gastroenterology"},{"key":"1240_CR101","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/hep.29179","volume":"67","author":"E Herrmann","year":"2018","unstructured":"Herrmann, E. et al. Assessment of biopsy-proven liver fibrosis by two-dimensional shear wave elastography: an individual patient data-based meta-analysis. Hepatology 67, 260\u2013272 (2018).","journal-title":"Hepatology"},{"key":"1240_CR102","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jhep.2019.08.019","volume":"71","author":"M Serra-Burriel","year":"2019","unstructured":"Serra-Burriel, M. et al. Transient elastography for screening of liver fibrosis: cost-effectiveness analysis from six prospective cohorts in Europe and Asia. J. Hepatol. 71, 1141\u20131151 (2019).","journal-title":"J. Hepatol."},{"key":"1240_CR103","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1002\/hep.30979","volume":"71","author":"L Asphaug","year":"2020","unstructured":"Asphaug, L., Thiele, M., Krag, A. & Melberg, H. O. Cost-effectiveness of noninvasive screening for alcohol-related liver fibrosis. Hepatology 71, 2093\u20132104 (2020).","journal-title":"Hepatology"},{"key":"1240_CR104","doi-asserted-by":"publisher","unstructured":"Israelsen, M. et al. Steatotic liver disease classification is dynamic, affecting clinical trial eligibility and subclass-specific treatments. Clin. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2025.02.007 (2025). A comprehensive study demonstrating how thresholds for self-reported alcohol use fluctuate over time.","DOI":"10.1016\/j.cgh.2025.02.007"},{"key":"1240_CR105","doi-asserted-by":"publisher","unstructured":"Diaz, L. A. et al. An expert consensus Delphi panel in MetALD: opportunities and challenges in clinical practice. Clin. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2025.02.017 (2025).","DOI":"10.1016\/j.cgh.2025.02.017"},{"key":"1240_CR106","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/add.13341","volume":"111","author":"A Kalinowski","year":"2016","unstructured":"Kalinowski, A. & Humphreys, K. Governmental standard drink definitions and low-risk alcohol consumption guidelines in 37 countries. Addiction 111, 1293\u20131298 (2016).","journal-title":"Addiction"},{"key":"1240_CR107","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.cgh.2024.01.006","volume":"22","author":"P Nasr","year":"2024","unstructured":"Nasr, P. et al. Misclassified alcohol-related liver disease is common in presumed metabolic dysfunction-associated steatotic liver disease and highly increases risk for future cirrhosis. Clin. Gastroenterol. Hepatol. 22, 1048\u20131057 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1240_CR108","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/mpr.204","volume":"16","author":"J Rehm","year":"2007","unstructured":"Rehm, J., Klotsche, J. & Patra, J. Comparative quantification of alcohol exposure as risk factor for global burden of disease. Int. J. Methods Psychiatr. Res. 16, 66\u201376 (2007).","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"1240_CR109","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","volume":"392","author":"GBD 2016 Alcohol Collaborators","year":"2018","unstructured":"GBD 2016 Alcohol Collaborators Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 392, 1015\u20131035 (2018).","journal-title":"Lancet"},{"key":"1240_CR110","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.3390\/jcm10091877","volume":"10","author":"M Castellana","year":"2021","unstructured":"Castellana, M. et al. Performance of fatty liver index in identifying non-alcoholic fatty liver disease in population studies. A meta-analysis. J. Clin. Med. 10, 1877 (2021).","journal-title":"J. Clin. Med."},{"key":"1240_CR111","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000386","volume":"8","author":"H Hagstr\u00f6m","year":"2024","unstructured":"Hagstr\u00f6m, H. et al. The future of international classification of diseases coding in steatotic liver disease: an expert panel delphi consensus statement. Hepatol. Commun. 8, e0386 (2024).","journal-title":"Hepatol. Commun."},{"key":"1240_CR112","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/apt.70012","volume":"61","author":"KM Schneider","year":"2025","unstructured":"Schneider, K. M. et al. The lipidomic profile discriminates between MASLD and MetALD. Aliment. Pharmacol. Ther. 61, 1357\u20131371 (2025).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1240_CR113","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1002\/hep.29631","volume":"67","author":"F \u00c5berg","year":"2018","unstructured":"\u00c5berg, F., Helenius-Hietala, J., Puukka, P., F\u00e4rkkil\u00e4, M. & Jula, A. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. Hepatology 67, 2141\u20132149 (2018).","journal-title":"Hepatology"},{"key":"1240_CR114","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.cgh.2019.06.036","volume":"18","author":"F \u00c5berg","year":"2020","unstructured":"\u00c5berg, F. et al. Combined effects of alcohol and metabolic disorders in patients with chronic liver disease. Clin. Gastroenterol. Hepatol. 18, 995\u2013997 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1240_CR115","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/jgh.14770","volume":"35","author":"P Sahlman","year":"2020","unstructured":"Sahlman, P. et al. Genetic and lifestyle risk factors for advanced liver disease among men and women. J. Gastroenterol. Hepatol. 35, 291\u2013298 (2020).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"1240_CR116","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1111\/liv.14830","volume":"41","author":"E Pose","year":"2021","unstructured":"Pose, E. et al. Interaction between metabolic syndrome and alcohol consumption, risk factors of liver fibrosis: a population-based study. Liver Int. 41, 1556\u20131564 (2021).","journal-title":"Liver Int."},{"key":"1240_CR117","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.cgh.2020.11.038","volume":"20","author":"M Israelsen","year":"2022","unstructured":"Israelsen, M. et al. Metabolic and genetic risk factors are the strongest predictors of severity of alcohol-related liver fibrosis. Clin. Gastroenterol. Hepatol. 20, 1784\u20131794 (2022).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1240_CR118","first-page":"890","volume":"11","author":"P Lemmer","year":"2022","unstructured":"Lemmer, P. et al. Effects of moderate alcohol consumption in non-alcoholic fatty liver disease. J. Clin. Med. Res. 11, 890 (2022).","journal-title":"J. Clin. Med. Res."},{"key":"1240_CR119","doi-asserted-by":"publisher","first-page":"100325","DOI":"10.1016\/j.jhepr.2021.100325","volume":"3","author":"M Israelsen","year":"2021","unstructured":"Israelsen, M. et al. Comprehensive lipidomics reveals phenotypic differences in hepatic lipid turnover in ALD and NAFLD during alcohol intoxication. JHEP Rep. 3, 100325 (2021).","journal-title":"JHEP Rep."},{"key":"1240_CR120","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1530\/EC-19-0317","volume":"8","author":"AR Lanng","year":"2019","unstructured":"Lanng, A. R. et al. Gluco-metabolic effects of oral and intravenous alcohol administration in men. Endocr. Connect. 8, 1372\u20131382 (2019).","journal-title":"Endocr. Connect."},{"key":"1240_CR121","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/j.gastro.2023.04.025","volume":"165","author":"DQ Huang","year":"2023","unstructured":"Huang, D. Q. et al. Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study. Gastroenterology 165, 463\u2013472 (2023).","journal-title":"Gastroenterology"},{"key":"1240_CR122","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/hep.23276","volume":"51","author":"K Promrat","year":"2010","unstructured":"Promrat, K. et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 51, 121\u2013129 (2010).","journal-title":"Hepatology"},{"key":"1240_CR123","doi-asserted-by":"publisher","unstructured":"Lee, B. P., Molina, J., Kim, S., Dodge, J. L. & Terrault, N. A. Association of alcohol and incremental cardiometabolic risk factors with liver disease: a national cross-sectional study. Clin. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2025.01.003 (2025).","DOI":"10.1016\/j.cgh.2025.01.003"},{"key":"1240_CR124","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jhep.2024.05.042","volume":"81","author":"JH Oh","year":"2024","unstructured":"Oh, J. H. et al. Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort. J. Hepatol. 81, 772\u2013780 (2024).","journal-title":"J. Hepatol."},{"key":"1240_CR125","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000718","volume":"9","author":"LA D\u00edaz","year":"2025","unstructured":"D\u00edaz, L. A. et al. Noninvasive pathway for stratifying fibrosis in suspected metabolic dysfunction and alcohol-associated liver disease (MetALD). Hepatol. Commun. 9, e0718 (2025).","journal-title":"Hepatol. Commun."},{"key":"1240_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(24)00708-6","author":"S Harrison","year":"2024","unstructured":"Harrison, S. et al. SAT-263 Resmetirom treatment of a subgroup of patients with possible MetALD enrolled in MAESTRO-NASH, a phase 3 NASH\/MASH serial liver biopsy study. J. Hepatol. https:\/\/doi.org\/10.1016\/s0168-8278(24)00708-6 (2024). A phase III trial supporting the use of resmetirom in MASLD, a promising therapy for MetALD.","journal-title":"J. Hepatol."},{"key":"1240_CR127","doi-asserted-by":"publisher","unstructured":"Sanyal, A. J. et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2413258 (2025). A phase III trial supporting the use of semaglutide in MASLD, a promising therapy for MetALD.","DOI":"10.1056\/NEJMoa2413258"},{"key":"1240_CR128","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","volume":"82","author":"CS Hendershot","year":"2025","unstructured":"Hendershot, C. S. et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry 82, 395\u2013405 (2025).","journal-title":"JAMA Psychiatry"},{"key":"1240_CR129","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s41575-025-01120-5","volume":"22","author":"LA Diaz","year":"2025","unstructured":"Diaz, L. A. et al. Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease. Nat. Rev. Gastroenterol. Hepatol. 22, 866\u2013884 (2025).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1240_CR130","doi-asserted-by":"publisher","unstructured":"Torp, N. et al. Phosphatidylethanol and self-reported alcohol intake to subclassify in individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study. Lancet Gastroenterol. Hepatol. https:\/\/doi.org\/10.1016\/S2468-1253(25)00187-6 (2025).","DOI":"10.1016\/S2468-1253(25)00187-6"},{"key":"1240_CR131","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.14309\/ajg.0000000000000340","volume":"114","author":"M Roerecke","year":"2019","unstructured":"Roerecke, M. et al. Alcohol consumption and risk of liver cirrhosis: a systematic review and meta-analysis. Am. J. Gastroenterol. 114, 1574\u20131586 (2019).","journal-title":"Am. J. Gastroenterol."},{"key":"1240_CR132","unstructured":"United Nations Department for Economic and Social Affairs. World Population Ageing 2019 Highlights (UN, 2020)."},{"key":"1240_CR133","doi-asserted-by":"publisher","first-page":"107690","DOI":"10.1016\/j.ypmed.2023.107690","volume":"175","author":"H Sun","year":"2023","unstructured":"Sun, H. et al. Global disease burden attributed to high sugar-sweetened beverages in 204 countries and territories from 1990 to 2019. Prev. Med. 175, 107690 (2023).","journal-title":"Prev. Med."},{"key":"1240_CR134","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/j.jhep.2023.07.007","volume":"80","author":"KM Schneider","year":"2024","unstructured":"Schneider, K. M. & Schneider, C. V. A new era for steatotic liver disease: evaluating the novel nomenclature in the UK Biobank. J. Hepatol. 80, e58\u2013e60 (2024).","journal-title":"J. Hepatol."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01240-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01240-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01240-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:02:12Z","timestamp":1787058132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-026-01240-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":134,"alternative-id":["1240"],"URL":"https:\/\/doi.org\/10.1038\/s41575-026-01240-6","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"15 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.P. declares consultancy fees for GlaxoSmithKline. R.L. serves as a consultant to Aardvark Therapeutics, Altimmune, Anylam\/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol\u00a0Myers Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89 bio, Terns Pharmaceuticals and Viking Therapeutics. In addition, his institutions received research grants from Arrowhead Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Bristol\u00a0Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Merck, Pfizer, Sonic Incytes and Terns Pharmaceuticals. He is a co-founder of LipoNexus Inc. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}